Connor Iapoce

Women with high social isolation and high loneliness scores had a 13.0% - 27.0% higher risk of incident CVD compared to women with low scores.

Dr. Radhakrishnan discusses both the effects of gender bias and why women don't get screened for heart disease.

On Wear Red Day, Dr. Ivanova advocates for increased awareness and diversity in women's cardiovascular care.

Our 5 experts return to examine the far-reaching repercussions of the COVID-19 pandemic on the physician burnout crisis.

The study suggested children born extremely premature may remain "preterm for life," with ophthalmic sequelae persisting into adulthood.

Rates of aspirin use for preeclampsia prophylaxis were observed in a minority of women with risk factors including pre-pregnancy diabetes, obesity, or chronic hypertension.

Dr. Modi discusses the pending approval of faricimab for nAMD, DME treatment and highlights important observations from phase 3 data.

Outlook Therapeutics is expected to submit a BLA to the FDA for the investigative ophthalmic bevacizumab-vikg formulation (ONS-5010).

TENAYA and LUCERNE show reduced treatment burden in nAMD patients, while vision gains and extended durability for DME patients were observed in YOSEMITE and RHINE.

Oral CAIS had a slightly higher, but small risk of severe adverse reaction compared to topical CAIS, which may help the reluctance to prescribe.

Joined by 5 experts in the field of burnout, Crisis Point uncovers the ways burnout manifests and the ramifications it has on both personal and professional lives.

The new guidelines conclude that current evidence is insufficient to assess the balance of benefits and harms of screening for AF in adults ≥50 years.

An increase of 57% in new-onset type 1 diabetes admissions was observed from March 2020 - 2021.

Early-pregnancy NT-proBNP level may be an important determinant of pregnancy outcomes and CV risk.

The prevalence of AHT decreased by 6.7% each year during the study period, but the number of patients with AHT who died remained stable.

Data show the change in CHD prevalence from 2011 - 2018 (6.2% to 6.0%) was statistically insignificant.

Data show among patients with focal FDG uptake, PET/MRI and inflammatory blood markers resolved at follow-up performed at a mean of 52 days after baseline.

Eye screening varied from 31.8% - 73.0%, with lower screening rates at smaller health systems.

Out-of-pocket costs for noninsulin medications were 84.4% to 95.2% lower in Medicaid than in Marketplace plans, while out-of-pocket costs for insulin were 76.7% to 94.7% lower.

Data show the 1-year incidence of the composite primary endpoint was 10.6% among patients randomized to FFR-guided PCI and 6.9% in CABG.

Optical treatment with DIMS was significantly associated with slower myopia progression compared to SVL treatment during the lockdown period.

Sexual activity was involved in 0.2% of all SCDs, with sudden arrhythmic death syndrome and cardiomyopathies predominant underlying causes.

The study suggests a platform that can be integrated into surgical ophthalmic microscopes can provide real-time audiovisual feedback to the surgeon during phacoemulsification cataract surgery.

Abbott's device is designed to create highly detailed 3-dimensional maps of the heart to help physicians identify and treat abnormal rhythms.

A study found psychotropic medication use was associated with a higher risk of 1 year all-cause mortality, regardless of self-reported symptoms of anxiety.

A recent study showed anticoagulant therapy for 6 weeks compared to 3 months met noninferiority criteria, based on a combination of recurrent VTE risk and bleeding risk.

Data show Black and White patients had a similar risk of MACE over a median 24.4-month follow-up.

Data show the persistence of fluid at 52 and 100 weeks was associated with worse VA, compared with eyes with recurrent ME or persistently dry macula.

From the pooled results of TRILOGY 1 and 2, data show 4 g/d of ω-3–PL/FFA reduced TG levels by 10.9% at 12 weeks and 12.7% at 26 weeks, relative to placebo.

The adjusted change in 24-hour systolic blood pressure from baseline to 12 weeks was −11.0 mm Hg in the chlorthalidone group and −0.5 mm Hg in the placebo group.